Think of Enterprise Value as the theoretical takeover price. It is more comprehensive than market capitalization (Market Cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.
EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, FIT Biotech Oy's Enterprise Value is €13.54 Mil.
FIT Biotech Oy's EBIT for the trailing twelve months (TTM) ended in Jun. 2018 was €-3.29 Mil. Therefore, FIT Biotech Oy's EV-to-EBIT ratio for today is -4.11.
EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA. As of today, FIT Biotech Oy's Enterprise Value is €13.54 Mil.
FIT Biotech Oy's EBITDA for the trailing twelve months (TTM) ended in Jun. 2018 was €-2.98 Mil. Therefore, FIT Biotech Oy's EV-to-EBITDA ratio for today is -4.55.
EV-to-Revenue is calculated as Enterprise Value divided by its Revenue. As of today, FIT Biotech Oy's Enterprise Value is €13.54 Mil.
FIT Biotech Oy's Revenue for the trailing twelve months (TTM) ended in Jun. 2018 was €0.00 Mil. Therefore, FIT Biotech Oy's EV-to-Revenue ratio for today is .
FIT Biotech Oy Enterprise Value Historical Data
The historical data trend for FIT Biotech Oy's Enterprise Value can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of FIT Biotech Oy's Enterprise Value
For the Biotechnology subindustry, FIT Biotech Oy's Enterprise Value, along with its competitors' market caps and Enterprise Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
FIT Biotech Oy's Enterprise Value Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, FIT Biotech Oy's Enterprise Value distribution charts can be found below:
* The bar in red indicates where FIT Biotech Oy's Enterprise Value falls into.
FIT Biotech Oy Enterprise Value Calculation
Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.
FIT Biotech Oy's Enterprise Value for the fiscal year that ended in Dec. 2017 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FIT Biotech Oy (OHEL:FITBIO) Enterprise Value Explanation
When an investor buy a company, the investor needs to pay not only the common shares, he/she also needs to pay the shareholders of Preferred Stocks. He also assumes the debt of the company, and receives the cash on the company's balance sheet.
If a company has more cash than debt, the investor actually pays less than the Market Cap because he immediately owns the cash once the transaction goes through.
The market value of Preferred Stock needs to be added to the market value of common stocks in the calculation of Enterprise Value.
For the companies with the same Market Cap, the smaller the Enterprise Value is, the cheaper the company is.
Enterprise Value can be negative when the company's net cash is more than its Market Cap. In this case the investor is basically getting the company for free and get paid for that.
1. EV-to-EBIT is calculated as Enterprise Value divided by its EBIT.
FIT Biotech Oy's current Enterprise Value is €13.54 Mil.
For company reported semi-annually or annually, GuruFocus uses latest annual data as the TTM data. FIT Biotech Oy's EBIT for the trailing twelve months (TTM) ended in Jun. 2018 was €-3.29 Mil.
2. EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA.
FIT Biotech Oy's current Enterprise Value is €13.54 Mil.
For company reported semi-annually or annually, GuruFocus uses latest annual data as the TTM data. FIT Biotech Oy's EBITDA for the trailing twelve months (TTM) ended in Jun. 2018 was €-2.98 Mil.
FIT Biotech Oy's current Enterprise Value is €13.54 Mil.
For company reported semi-annually or annually, GuruFocus uses latest annual data as the TTM data. FIT Biotech Oy's Revenue for the trailing twelve months (TTM) ended in Jun. 2018 was €0.00 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FIT Biotech Oy Enterprise Value Related Terms
Thank you for viewing the detailed overview of FIT Biotech Oy's Enterprise Value provided by GuruFocus.com. Please click on the following links to see related term pages.
FIT Biotech Oy is a clinical-stage biotechnology company. It is primarily focused on developing antibody therapies for cancer immunotherapy as well as Deoxyribonucleic acid (DNA) vaccines for the prevention of infectious diseases such as Human immunodeficiency virus (HIV). The firm's GTU technology enables the production of antibodies in the human body instead of using industrially manufactured antibodies. The GTU technology platform has various application areas. The group generates revenue through the sales of services related to the HIV vaccine. The organization is based in Finland.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
OHEL:FITBIO has been successfully added to your 